NASDAQ:RDHL Redhill Biopharma (RDHL) Stock Price, News & Analysis $0.57 -0.02 (-4.13%) Closing price 09/18/2026 03:59 PM EasternExtended Trading$0.56 -0.01 (-0.93%) As of 09/18/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Redhill Biopharma Stock (NASDAQ:RDHL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Redhill Biopharma alerts:Sign Up Key Stats Today's Range$0.56▼$0.5950-Day Range$0.55▼$0.9052-Week Range$0.54▼$2.79Volume80,997 shsAverage Volume5.62 million shsMarket Capitalization$3.46 millionP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and certain infectious diseases. The company was founded in Israel and conducted operations primarily in the United States, where it pursued regulatory approval, commercialization and clinical development activities. RedHill’s principal commercial product was Talicia, an oral combination of rifabutin, amoxicillin and omeprazole approved by the U.S. Food and Drug Administration to treat Helicobacter pylori infection in adults. The company also commercialized Aemcolo, an oral, locally acting antibiotic formulation based on rifamycin for certain cases of travelers’ diarrhea. Its development pipeline included investigational treatments for gastrointestinal disorders, infections and other conditions, although not all of these programs reached approval. RedHill was led for several years by Mark L. Sirgo, who served as president and chief executive officer. The company’s shares traded on the Nasdaq Capital Market under the symbol RDHL; however, RedHill subsequently faced significant operating and financial challenges, and its public-market listing and business activities were materially reduced. Information about its current operations and leadership may therefore be limited.AI Generated. May Contain Errors. Read More Redhill Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreRDHL MarketRank™: Redhill Biopharma scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRedhill Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRedhill Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Redhill Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.93.Price to Book Value per Share RatioRedhill Biopharma has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the float of Redhill Biopharma has been sold short.Short Interest Ratio / Days to CoverRedhill Biopharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Redhill Biopharma has recently decreased by 43.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRedhill Biopharma does not currently pay a dividend.Dividend GrowthRedhill Biopharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Redhill Biopharma this week, compared to 1 article on an average week.Search Interest3 people have searched for RDHL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Redhill Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders6.81% of the stock of Redhill Biopharma is held by insiders.Percentage Held by Institutions7.20% of the stock of Redhill Biopharma is held by institutions.Read more about Redhill Biopharma's insider trading history. Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redhill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDHL Stock News HeadlinesNovartis (NYSE:NVS) versus Redhill Biopharma (NASDAQ:RDHL) Head-To-Head ReviewSeptember 16, 2026 | americanbankingnews.comRedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?September 10, 2026 | finance.yahoo.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Redhill Biopharma (NASDAQ:RDHL) Stock Passes Below 200-Day Moving Average - Should You Sell?September 9, 2026 | americanbankingnews.comRedhill Biopharma stock doubles in one session — here's whySeptember 1, 2026 | msn.comRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®September 1, 2026 | markets.businessinsider.comRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®September 1, 2026 | prnewswire.comRedHill Biopharma Stock Surges 64% Over Deal To Divest Talicia BusinessAugust 31, 2026 | rttnews.comSee More Headlines RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed this year? Redhill Biopharma's stock was trading at $1.03 at the start of the year. Since then, RDHL shares have decreased by 44.8% and is now trading at $0.5683. How were Redhill Biopharma's earnings last quarter? Redhill Biopharma Ltd. (NASDAQ:RDHL) announced its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($480.00) by $20.00. The biotechnology company earned $21.61 million during the quarter, compared to analyst estimates of $23.41 million. When did Redhill Biopharma's stock split? Redhill Biopharma shares reverse split before market open on Tuesday, August 20th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Redhill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Redhill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Redhill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), AbbVie (ABBV). Company Calendar Last Earnings11/30/2021Today9/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RDHL's financial health is in the Yellow zone, according to TradeSmith. RDHL has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RDHL Previous SymbolASX:RDH CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees210Year Founded2009Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$290 thousand Price / Sales11.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.68Miscellaneous Outstanding Shares6,080,000Free Float5,667,000Market Cap$3.46 million OptionableNo Data Beta4.96 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:RDHL) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
